Predicted non-responders were randomly assigned ( @:@ ) to receive four cycles of docetaxel ( @ mg/m ( @ ) intravenously every @ weeks ) and trastuzumab ( @ mg/kg intravenously every @ weeks ) plus bevacizumab ( @ mg/kg intravenously every @ weeks ; group A ) or continue on docetaxel plus trastuzumab alone ( group B ) .